Concepts (242)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Single-Cell Analysis | 3 | 2021 | 35 | 1.090 |
Why?
|
| Flow Cytometry | 5 | 2021 | 489 | 0.950 |
Why?
|
| Programmed Cell Death 1 Receptor | 3 | 2021 | 86 | 0.950 |
Why?
|
| Monocytes | 1 | 2022 | 210 | 0.810 |
Why?
|
| High-Throughput Screening Assays | 1 | 2021 | 48 | 0.770 |
Why?
|
| CD8-Positive T-Lymphocytes | 6 | 2022 | 265 | 0.760 |
Why?
|
| Drug Discovery | 1 | 2021 | 94 | 0.730 |
Why?
|
| Immunologic Memory | 6 | 2019 | 75 | 0.710 |
Why?
|
| Immunotherapy | 4 | 2022 | 212 | 0.670 |
Why?
|
| Neoplasms | 5 | 2022 | 1660 | 0.660 |
Why?
|
| Interleukin-2 | 4 | 2012 | 133 | 0.630 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 560 | 0.590 |
Why?
|
| Receptors, Immunologic | 2 | 2007 | 72 | 0.550 |
Why?
|
| Homeostasis | 5 | 2012 | 291 | 0.530 |
Why?
|
| Melanoma | 1 | 2018 | 335 | 0.480 |
Why?
|
| Neutrophils | 4 | 2020 | 204 | 0.470 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2010 | 42 | 0.370 |
Why?
|
| Mice | 15 | 2022 | 8472 | 0.370 |
Why?
|
| Killer Cells, Natural | 4 | 2013 | 94 | 0.360 |
Why?
|
| Interleukin-15 | 3 | 2022 | 66 | 0.340 |
Why?
|
| Mice, Knockout | 10 | 2018 | 1692 | 0.340 |
Why?
|
| Immunologic Surveillance | 1 | 2008 | 10 | 0.340 |
Why?
|
| Macrophages | 3 | 2022 | 647 | 0.330 |
Why?
|
| Chemokines | 1 | 2008 | 119 | 0.320 |
Why?
|
| Animals | 21 | 2022 | 20877 | 0.310 |
Why?
|
| Biomarkers | 5 | 2021 | 1593 | 0.300 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 4 | 2012 | 32 | 0.300 |
Why?
|
| Mice, Inbred C57BL | 10 | 2020 | 2790 | 0.290 |
Why?
|
| T-Lymphocytes | 4 | 2018 | 595 | 0.290 |
Why?
|
| Cell Differentiation | 2 | 2022 | 1034 | 0.290 |
Why?
|
| Humans | 27 | 2022 | 68525 | 0.270 |
Why?
|
| Th1 Cells | 2 | 2009 | 101 | 0.260 |
Why?
|
| Inflammation | 3 | 2022 | 1030 | 0.260 |
Why?
|
| Poliovirus Vaccine, Oral | 1 | 2004 | 2 | 0.250 |
Why?
|
| Poliovirus Vaccine, Inactivated | 1 | 2004 | 2 | 0.250 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 3 | 2019 | 41 | 0.250 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2005 | 226 | 0.240 |
Why?
|
| Integrins | 1 | 2004 | 115 | 0.240 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 211 | 0.240 |
Why?
|
| Endothelial Cells | 4 | 2019 | 384 | 0.230 |
Why?
|
| Lung Neoplasms | 3 | 2020 | 1172 | 0.230 |
Why?
|
| Anaphylatoxins | 1 | 2022 | 3 | 0.220 |
Why?
|
| Th17 Cells | 2 | 2021 | 116 | 0.220 |
Why?
|
| Cerebellar Neoplasms | 1 | 2022 | 17 | 0.220 |
Why?
|
| Medulloblastoma | 1 | 2022 | 24 | 0.220 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 444 | 0.210 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2021 | 6 | 0.210 |
Why?
|
| Immunologic Factors | 1 | 2022 | 87 | 0.210 |
Why?
|
| Disease Susceptibility | 1 | 2022 | 179 | 0.200 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2021 | 66 | 0.200 |
Why?
|
| Carcinogenesis | 3 | 2020 | 124 | 0.200 |
Why?
|
| Metabolomics | 1 | 2021 | 28 | 0.200 |
Why?
|
| Down-Regulation | 1 | 2022 | 447 | 0.190 |
Why?
|
| Lymphocyte Activation | 5 | 2016 | 397 | 0.190 |
Why?
|
| Cell Proliferation | 5 | 2016 | 1173 | 0.180 |
Why?
|
| Latent TGF-beta Binding Proteins | 1 | 2020 | 14 | 0.180 |
Why?
|
| Genomics | 1 | 2021 | 167 | 0.180 |
Why?
|
| Immune Evasion | 1 | 2020 | 19 | 0.180 |
Why?
|
| Proteolysis | 1 | 2020 | 97 | 0.180 |
Why?
|
| Thrombin | 1 | 2020 | 117 | 0.170 |
Why?
|
| Receptors, CXCR4 | 1 | 2019 | 48 | 0.170 |
Why?
|
| Mouth Neoplasms | 1 | 2021 | 206 | 0.170 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 101 | 0.170 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2019 | 21 | 0.170 |
Why?
|
| Antigen-Antibody Complex | 2 | 2010 | 175 | 0.170 |
Why?
|
| Proteomics | 1 | 2021 | 246 | 0.170 |
Why?
|
| Thiazolidines | 1 | 2018 | 23 | 0.170 |
Why?
|
| Embryonic Development | 1 | 2019 | 100 | 0.170 |
Why?
|
| Blood Platelets | 1 | 2020 | 284 | 0.170 |
Why?
|
| Brain Neoplasms | 1 | 2022 | 371 | 0.160 |
Why?
|
| Mice, Inbred BALB C | 4 | 2020 | 532 | 0.160 |
Why?
|
| Rectal Prolapse | 1 | 2018 | 5 | 0.160 |
Why?
|
| Neoplasms, Experimental | 1 | 2018 | 118 | 0.160 |
Why?
|
| Biphenyl Compounds | 1 | 2018 | 184 | 0.160 |
Why?
|
| Multiple Sclerosis | 1 | 2019 | 132 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 1 | 2018 | 87 | 0.160 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 304 | 0.160 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2018 | 131 | 0.150 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2019 | 268 | 0.150 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 207 | 0.150 |
Why?
|
| Listeriosis | 1 | 2016 | 7 | 0.150 |
Why?
|
| Listeria monocytogenes | 1 | 2016 | 15 | 0.140 |
Why?
|
| Disease Models, Animal | 2 | 2022 | 2550 | 0.140 |
Why?
|
| Streptococcus pyogenes | 1 | 2016 | 20 | 0.140 |
Why?
|
| Colitis | 1 | 2018 | 156 | 0.140 |
Why?
|
| Immunity | 1 | 2016 | 67 | 0.140 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2021 | 624 | 0.140 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2018 | 167 | 0.140 |
Why?
|
| Extracellular Traps | 1 | 2016 | 9 | 0.140 |
Why?
|
| Narcolepsy | 1 | 2016 | 45 | 0.140 |
Why?
|
| Streptococcal Infections | 1 | 2016 | 53 | 0.140 |
Why?
|
| Receptors, Complement | 1 | 2016 | 58 | 0.140 |
Why?
|
| Intestine, Small | 1 | 2016 | 89 | 0.130 |
Why?
|
| Blood Coagulation | 1 | 2016 | 123 | 0.130 |
Why?
|
| Cytokines | 5 | 2020 | 866 | 0.130 |
Why?
|
| Membrane Proteins | 1 | 2020 | 617 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 2 | 2010 | 510 | 0.130 |
Why?
|
| Receptors, Cell Surface | 1 | 2016 | 248 | 0.130 |
Why?
|
| Lymphocytes | 2 | 2020 | 228 | 0.130 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2018 | 300 | 0.130 |
Why?
|
| Dendritic Cells | 2 | 2013 | 201 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 467 | 0.130 |
Why?
|
| Proteins | 1 | 2018 | 473 | 0.120 |
Why?
|
| Immunophenotyping | 3 | 2019 | 110 | 0.120 |
Why?
|
| Infectious Mononucleosis | 1 | 2013 | 7 | 0.120 |
Why?
|
| Computational Biology | 1 | 2015 | 190 | 0.120 |
Why?
|
| Lymphatic Vessels | 1 | 2013 | 5 | 0.120 |
Why?
|
| Interleukin-15 Receptor alpha Subunit | 1 | 2013 | 10 | 0.120 |
Why?
|
| Interleukin-7 | 1 | 2013 | 18 | 0.120 |
Why?
|
| Epidermis | 1 | 2013 | 42 | 0.120 |
Why?
|
| Phenotype | 3 | 2016 | 946 | 0.120 |
Why?
|
| Psoriasis | 1 | 2013 | 46 | 0.110 |
Why?
|
| Software | 1 | 2015 | 418 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2012 | 135 | 0.110 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2013 | 126 | 0.110 |
Why?
|
| Mice, Transgenic | 3 | 2019 | 1032 | 0.110 |
Why?
|
| Directed Molecular Evolution | 1 | 2012 | 6 | 0.110 |
Why?
|
| Lung Transplantation | 1 | 2013 | 88 | 0.110 |
Why?
|
| Mutant Proteins | 1 | 2012 | 45 | 0.110 |
Why?
|
| Protein Engineering | 1 | 2012 | 35 | 0.110 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2022 | 376 | 0.100 |
Why?
|
| Signal Transduction | 4 | 2022 | 2688 | 0.090 |
Why?
|
| Pulmonary Edema | 1 | 2010 | 37 | 0.090 |
Why?
|
| Graft Rejection | 1 | 2013 | 458 | 0.090 |
Why?
|
| Melanoma, Experimental | 1 | 2010 | 95 | 0.090 |
Why?
|
| Homeodomain Proteins | 1 | 2010 | 157 | 0.090 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 742 | 0.080 |
Why?
|
| Cells, Cultured | 2 | 2016 | 2673 | 0.070 |
Why?
|
| Middle Aged | 7 | 2020 | 21119 | 0.070 |
Why?
|
| Disease Progression | 3 | 2020 | 1037 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2019 | 282 | 0.070 |
Why?
|
| Bone Marrow | 1 | 2007 | 168 | 0.070 |
Why?
|
| Lung | 1 | 2010 | 849 | 0.070 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2021 | 199 | 0.060 |
Why?
|
| Poliovirus | 1 | 2004 | 4 | 0.060 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2004 | 8 | 0.060 |
Why?
|
| In Vitro Techniques | 1 | 2005 | 765 | 0.060 |
Why?
|
| Adult | 6 | 2020 | 21375 | 0.060 |
Why?
|
| Immunization | 1 | 2004 | 86 | 0.060 |
Why?
|
| Th2 Cells | 2 | 2016 | 48 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2021 | 7028 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2004 | 411 | 0.060 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2022 | 13 | 0.060 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2022 | 20 | 0.050 |
Why?
|
| Hedgehog Proteins | 1 | 2022 | 38 | 0.050 |
Why?
|
| Mutation | 2 | 2021 | 1213 | 0.050 |
Why?
|
| Healthy Volunteers | 1 | 2022 | 78 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2021 | 29 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 51 | 0.050 |
Why?
|
| Janus Kinase 2 | 1 | 2021 | 40 | 0.050 |
Why?
|
| Algorithms | 2 | 2019 | 1194 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 104 | 0.050 |
Why?
|
| Models, Immunological | 2 | 2012 | 25 | 0.050 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2021 | 107 | 0.050 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2020 | 35 | 0.050 |
Why?
|
| GPI-Linked Proteins | 1 | 2020 | 27 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2021 | 714 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 370 | 0.040 |
Why?
|
| Aged | 4 | 2020 | 14842 | 0.040 |
Why?
|
| Primates | 1 | 2019 | 14 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 498 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2020 | 230 | 0.040 |
Why?
|
| Cell Adhesion Molecules | 1 | 2020 | 199 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2019 | 57 | 0.040 |
Why?
|
| Cell Separation | 1 | 2019 | 132 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2020 | 330 | 0.040 |
Why?
|
| Child | 2 | 2022 | 6400 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 4843 | 0.040 |
Why?
|
| Male | 5 | 2020 | 37281 | 0.040 |
Why?
|
| Chemokine CXCL2 | 1 | 2018 | 13 | 0.040 |
Why?
|
| Chemokine CXCL1 | 1 | 2018 | 21 | 0.040 |
Why?
|
| Female | 5 | 2020 | 38015 | 0.040 |
Why?
|
| Cell Membrane | 1 | 2020 | 523 | 0.040 |
Why?
|
| Peroxidase | 1 | 2018 | 40 | 0.040 |
Why?
|
| Protons | 1 | 2018 | 57 | 0.040 |
Why?
|
| Dextran Sulfate | 1 | 2018 | 88 | 0.040 |
Why?
|
| Antibodies | 1 | 2018 | 241 | 0.040 |
Why?
|
| Chemokine CCL2 | 1 | 2018 | 101 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2018 | 201 | 0.040 |
Why?
|
| Interleukin-10 | 1 | 2018 | 144 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 756 | 0.040 |
Why?
|
| Intestinal Mucosa | 1 | 2018 | 219 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2018 | 241 | 0.040 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2018 | 144 | 0.040 |
Why?
|
| Protein Binding | 1 | 2020 | 1027 | 0.040 |
Why?
|
| Bacterial Load | 1 | 2016 | 24 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2018 | 618 | 0.040 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2016 | 26 | 0.040 |
Why?
|
| Hemostasis | 1 | 2016 | 32 | 0.040 |
Why?
|
| Intestinal Neoplasms | 1 | 2016 | 30 | 0.030 |
Why?
|
| Influenza Vaccines | 1 | 2016 | 56 | 0.030 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2016 | 41 | 0.030 |
Why?
|
| Hematopoiesis | 1 | 2016 | 108 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 331 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 799 | 0.030 |
Why?
|
| Complement Pathway, Alternative | 1 | 2016 | 69 | 0.030 |
Why?
|
| Vaccination | 1 | 2016 | 182 | 0.030 |
Why?
|
| Complement Activation | 1 | 2016 | 145 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2016 | 329 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 2093 | 0.030 |
Why?
|
| HIV Infections | 1 | 2002 | 775 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2016 | 626 | 0.030 |
Why?
|
| Receptors, Interleukin-15 | 1 | 2013 | 7 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2018 | 1663 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2013 | 138 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 1849 | 0.030 |
Why?
|
| Cell Movement | 1 | 2016 | 630 | 0.030 |
Why?
|
| Keratinocytes | 1 | 2013 | 68 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2013 | 238 | 0.030 |
Why?
|
| Stromal Cells | 1 | 2013 | 113 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2013 | 156 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1548 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2013 | 237 | 0.030 |
Why?
|
| Interleukin-2 Receptor beta Subunit | 1 | 2012 | 7 | 0.030 |
Why?
|
| STAT5 Transcription Factor | 1 | 2012 | 18 | 0.030 |
Why?
|
| Surface Plasmon Resonance | 1 | 2012 | 50 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2012 | 160 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2013 | 244 | 0.030 |
Why?
|
| Models, Biological | 1 | 2016 | 981 | 0.030 |
Why?
|
| Crystallography, X-Ray | 1 | 2012 | 190 | 0.030 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2012 | 107 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2012 | 362 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 770 | 0.020 |
Why?
|
| Binding Sites | 1 | 2012 | 631 | 0.020 |
Why?
|
| Mice, Congenic | 1 | 2010 | 13 | 0.020 |
Why?
|
| Antibodies, Blocking | 1 | 2010 | 17 | 0.020 |
Why?
|
| Receptors, Fc | 1 | 2010 | 19 | 0.020 |
Why?
|
| Half-Life | 1 | 2010 | 96 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2012 | 546 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 4655 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2016 | 3185 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 1199 | 0.020 |
Why?
|
| Interleukin-17 | 1 | 2009 | 62 | 0.020 |
Why?
|
| Immune Tolerance | 1 | 2009 | 114 | 0.020 |
Why?
|
| Cell Line | 1 | 2012 | 1752 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2010 | 481 | 0.020 |
Why?
|
| Cell Survival | 1 | 2009 | 901 | 0.020 |
Why?
|
| United States | 1 | 2018 | 7335 | 0.020 |
Why?
|
| Adolescent | 1 | 2016 | 8903 | 0.010 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 2002 | 8 | 0.010 |
Why?
|
| Perforin | 1 | 2002 | 12 | 0.010 |
Why?
|
| Cytomegalovirus Infections | 1 | 2002 | 69 | 0.010 |
Why?
|